Clinicopathological study of fractional exhaled nitric oxide dynamics and intratumoral inducible nitric oxide synthase expression in primary lung cancer patients

Inducible nitric oxide synthase (iNOS) is expressed in non-small cell lung cancer (NSCLC) tumor cells and contributes to tumorigenesis. Nitric oxide, an indicator of airway inflammation, is concurrently produced in the airway epithelium. However, the interrelationships and predictive importance of iNOS remain unclear. This study aimed to investigate whether iNOS could serve as a novel biomarker for NSCLC.